DIA Global Forum
Current pharmacovigilance (PV) practices have evolved largely in response to medication-related disasters, particularly thalidomide. The current basis for identifying previously unrecognized hazards of medications in clinical use remains primarily the collection, evaluation, and communication of anecdotal reports of suspected adverse drug reactions (sADRs).
However, the rapidly developing availability of comprehensive and reliable medical information is driving new initiatives for transforming today’s primarily reactive PV system into one that is proactive, robust, and of greater clinical utility.
Read the full article.DIA Global Forum Dec 2013